Corbus Pharmaceuticals Holdings Inc. operates as a clinical-stage precision biopharmaceutical enterprise focused on discovering, developing, and commercializing transformative medicines for serious diseases. Its primary business operations center on advancing targeted oncology therapies—such as antibody-drug conjugates directed against Nectin-4—and novel metabolic treatments for obesity through rigorous clinical development pipelines to address significant unmet medical needs.